37.10↑0.80 (2.20%)
12:00 AM,29th Sep 202337.15↑0.82 (2.26%)
12:00 AM,29th Sep 2023BSE : 500288
NSE : MOREPENLAB
Sector : Health care
ISIN Code : INE083A01026
Last Updated: Sep 29 2023 | 12:00 AM IST
Market Cap (₹ Cr) | 1896 |
Turnover (₹ Cr) | 1.02 |
Volume (Shares) | 2748499 |
Face Value | 2 |
52-WK High | 48.45 |
52-WK High Date | 26 Dec 2022 |
52-WK Low | 23.60 |
52-WK Low Date | 03 Oct 2022 |
All Time High | 218.00 |
All Time High Date | 30 Mar 2000 |
All Time Low | 2.05 |
All Time Low Date | 07 Aug 2013 |
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine Montelukast Sodium Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories such as antibiotics gastrointestinal respiratory analgesic antiallergic and neuropsychiatry with brands such as Saltum Saltumax Cefpopen Cefpen-S Dom-DT Acifix Rabipen- DSR and Montelast. It has new products added to the therapeutic categories including Kilbac Ducal D Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992 the company set up the new facilities for bulk manufacture of Cephalexin 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993 the company started implementing its expansion plans for manufacture Cephalexin 7ADCA CIMC Chloride Research and Development Block and Formulation unit. The company introduced two latest molecules Ketrolac Tromethamine and Omeprazole. Also the company also launched Loratadine and Cisapride. During the year 1993-1994 the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine which is a potent analgesic. During the year 1994-1995 the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.During the year 1995-1996 the company successfully launched high value and high technology products namely Cisapride & Loratadine. Also the company launched herbal product namely Paclitaxel an anti cancer drug. During the year 1996-1997 the company commissioned its own formulation unit which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001 the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland a proven international leader in blood group serology diagnostic products. Also the company developed and launched wide range of contemporary lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.During the year 2001-2002 the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005 the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year the company started finalizing marketing partner for filing ANDA's for the molecule. During the year 2005-2006 the company made 52 DMF filing across ten European countries for six products. Also the company broadened its offering by introduced new product like Ducal Rythmix Montelast Alcoflam Levopen Moezole and Cefpen-S. During the year 2006-2007 the company improved its presence in the key market of South East Asia Africa & Australia. During the year the company acquired more than fifty new prospective customers in Korea Japan and Taiwan. During the year the company started of OTC formulation under the umberalla brand 'Dr. Morepen'. During the year 2007-2008 the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor USA (for immuunohematology system & consumables) Teco Medical Instruments Germany (for coagulation system & consumables) InTec INC. (for ELISA Kits) Access Bio USA (for Rapid Malaria Kits) helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 1896 |
EPS - TTM (₹) [S] | 1.08 |
P/E Ratio (X) [S] | 2.43 |
Face Value (₹) | 2 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 15.26 |
P/B Ratio (₹) [S] | 2.43 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Motilal Oswal Nifty Microcap 250 Index Fund-Reg (G) | 0.91 | 235297 | 0.28 |
Motilal Oswal Nifty Microcap 250 Index Fund-Dir (G) | 0.91 | 235297 | 0.28 |
Motilal Oswal S&P BSE Healthcare ETF | 0.01 | 2606 | 0.13 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 36.25 37.50 |
Week Low/High | 35.90 38.00 |
Month Low/High | 35.65 42.00 |
Year Low/High | 23.60 48.00 |
All time Low/High | 2.05 218.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 2.06% | 1.92% | -0.27 | -0.18% |
1 Month | -5.79% | -5.84% | 1.16 | 1.53% |
3 Month | 20.77% | 20.85% | 2.99 | 3.51% |
6 Month | 50.81% | 51.12% | 14.26 | 15.85% |
1 Year | 52.36% | 52.67% | 16.70 | 16.77% |
3 Year | 58.55% | 58.89% | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
27-03-2023 | KAMLESH PUROHIT | NSE | BUY | 5621570 | 27.62 |
27-03-2023 | KAMLESH PUROHIT | NSE | SELL | 5621570 | 27.43 |
26-12-2022 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 4320405 | 41.78 |
26-12-2022 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 4320405 | 41.68 |
23-12-2022 | QE SECURITIES | NSE | SELL | 4676848 | 40.90 |
23-12-2022 | QE SECURITIES | NSE | BUY | 4524621 | 40.98 |
23-12-2022 | TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED | NSE | BUY | 2833856 | 40.90 |
23-12-2022 | TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED | NSE | SELL | 3082901 | 40.93 |
22-12-2022 | QE SECURITIES | NSE | BUY | 3030456 | 36.51 |
22-12-2022 | QE SECURITIES | NSE | SELL | 3349734 | 36.44 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 38.22 |
Financial Institutions Banks | 0.98 |
Foreign Institutional Investors | 1.00 |
Insurance Companies | 1.06 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.30 |
Indian Public | 45.49 |
Others Non Institutional Investors | 12.95 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman & Managing Director : Sushil Suri
Non-Exec. & Independent Dir. : Manoj Joshi
Non-Exec. & Independent Dir. : Bhupender Raj Wadhwa
Non-Exec. & Independent Dir. : Sukhcharan singh
Company Sec. & Compli. Officer : Vipul Kumar Srivatava
Whole-time Director : Sanjay Suri
Non-Exec. & Independent Dir. : Praveen Kumar Dutt
Non-Exec. & Independent Dir. : Savita
Registered Office: Morepen Village, Nalagarh Road Near Baddi,Solan,Himachal Pradesh-173205 Ph: 91-01795-276201-03
Email:investors@morepen.com